ERYTECH tiendra un webcast le 11 septembre 2018 à l’occasion de ses résultats semestriels 2018
06 sept. 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, 06 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant...
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
15 juin 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
30 mai 2018 01h30 HE
|
Erytech Pharma S.A.
LYON, France, May 30, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
14 mai 2018 16h30 HE
|
Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
ERYTECH annonce le dépôt de son Document de Référence 2017 et de son Form 20-F 2017
24 avr. 2018 16h30 HE
|
Erytech Pharma S.A.
LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire...
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
24 avr. 2018 16h30 HE
|
Erytech Pharma S.A.
LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of...
Carcinoembryonic Antigen Market to hit $2.7bn by 2023: Global Market Insights, Inc.
20 avr. 2017 06h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, April 20, 2017 (GLOBE NEWSWIRE) -- The research report “Carcinoembryonic Antigen (CEA) Market Size By Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer),...
Carcinoembryonic antigen (CEA) market size worth $2.78 Billion by 2023: Global Market Insights Inc.
16 mai 2016 07h30 HE
|
Global Market Insights, Inc
Dover, DE, May 16, 2016 (GLOBE NEWSWIRE) -- Carcinoembryonic antigen (CEA) market size is forecast to reach USD 2.78 billion by 2023; as reported in the latest study by Global Market Insights,...
OncoMed to Present at Upcoming Investment Conferences
28 mai 2015 16h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cell (CSC) and...